Korro Bio Inc. Common Stock (KRRO)

About KRRO

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA ed…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

57

Website

www.korrobio.com/

Fundamentals

1-day range

$12.8$13.42

Market cap

$154.90M

P/E (trailing)

—

P/E (forward)

-2.90

EPS (trailing)

$-10.00

Dividend yield

—

Beta

3.12

Avg. volume

182.0K

Forecasts

10 analyst ratings

Korro Bio Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• KRRO

  Korro Bio Inc. Common Stock

  $12.94

  ▼ 2.41%
  Market cap $154.90MP/E —
  $5.2$55.89
• AARD

  Aardvark Therapeutics Inc. Common Stock

  $5.71

  ▼ 13.75%
  Market cap $154.94MP/E —
  $3.35$17.94
• CNTN

  Canton Strategic Holdings Inc. Common Stock

  $2.23

  ▼ 5.32%
  Market cap $154.25MP/E —
  $1.75$7.25
• MENS

  Jyong Biotech Ltd. Ordinary Shares

  $2.37

  ▲ 3.04%
  Market cap $152.06MP/E —
  $1.43$67
• OKUR

  OnKure Therapeutics Inc. Class A Common Stock

  $3.78

  ▼ 1.31%
  Market cap $162.39MP/E —
  $2.23$5.38
• LFCR

  Lifecore Biomedical Inc. Common Stock

  $4.58

  ▲ 0.88%
  Market cap $164.67MP/E —
  $3.63$8.98
• KZIA

  Kazia Therapeutics Limited American Depositary Shares

  $13.59

  ▼ 19.59%
  Market cap $141.81MP/E —
  $4.86$17.4

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Target
  benzinga · 8/20/2026

Institutional Ownership

March 31, 2026

Total shares held

12.92M

Total value held

$145.41M

Institutional holders

94